The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | An insight into the future treatment of AL amyloidosis
In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, shares her insights into the future treatment landscape of light chain (AL) amyloidosis. Dr Sanchorawala mentions the importance of early diagnosis, increased awareness and newer treatment regimens opening the doors for a brighter future in AL amyloidosis treatment. Dr Sanchorawala also discusses the EMN 23 clinical trial (NCT04131309), which reports on the use of subcutaneous daratumumab in stage 3B patients with advanced cardiac involvement. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Disclosures
Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Membership on an entity’s Board of Directors or advisory committees; Proclara: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.
